Anti-UGPase antibody [EPR10627(B)]

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-UGPase antibody [EPR10627(B)] (AB154817)

Immunohistochemical analysis of paraffin embedded Human skeletal muscle tissue using ab154817 showing +ve staining.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-UGPase antibody [EPR10627(B)] (AB154817)

Immunohistochemical analysis of paraffin embedded Human normal liver tissue using ab154817 showing +ve staining.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-UGPase antibody [EPR10627(B)] (AB154817)

Immunohistochemical analysis of paraffin-embedded Human colon adenocarcinoma labeling UGPase using ab154817 at 1/50 dilution.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-UGPase antibody [EPR10627(B)] (AB154817)

Immunohistochemical analysis of paraffin embedded Human normal heart tissue using ab154817 showing +ve staining.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-UGPase antibody [EPR10627(B)] (AB154817)

Immunohistochemical analysis of paraffin-embedded Human kidney labeling UGPase using ab154817 at 1/50 dilution.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-UGPase antibody [EPR10627(B)] (AB154817)

Immunohistochemical analysis of paraffin embedded Human normal colon tissue using ab154817 showing +ve staining.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

• Flow Cyt (Intra)

Unknown

Flow Cytometry (Intracellular) - Anti-UGPase antibody [EPR10627(B)] (AB154817)

Intracellular flow cytometric analysis of permeabilized NIH 3T3 cells labeling UGPase using ab154817 (red) at 1/10 dilution or a rabbit IgG (negative) (green).

• WB

Unknown

Western blot - Anti-UGPase antibody [EPR10627(B)] (AB154817)

All lanes:

Western blot - Anti-UGPase antibody [EPR10627(B)] (ab154817) at 1/1000 dilution

Lane 1:

HepG2 cell lysate at 10 µg

Lane 2:

HeLa cell lysate at 10 µg

Lane 3:

NIH 3T3 cell lysate at 10 µg

Lane 4:

Human fetal liver tissue lysate at 10 µg

Predicted band size: 57 kDa

false

• WB

AbReview45228****

Western blot - Anti-UGPase antibody [EPR10627(B)] (AB154817)

Lanes 1 - 2:

Western blot - Anti-UGPase antibody [EPR10627(B)] (ab154817) at 1/10000 dilution

Lanes 3 - 4:

Western blot - Anti-UGPase antibody [EPR10627(B)] (ab154817) at 1/20000 dilution

Lanes 5 - 6:

Western blot - Anti-UGPase antibody [EPR10627(B)] (ab154817)

All lanes:

Pig muscle sarcoplasm tissue lysate at 40 µg

Secondary

All lanes:

HRP-conjugated goat anti-rabbit IgG (H+L) polyclonal at 1/10000 dilution

Predicted band size: 57 kDa

Observed band size: 45-47 kDa

true

Exposure time: 5min

This image is courtesy of an Abreview submitted by Shannon Cruzen

• WB

CiteAb

Western blot - Anti-UGPase antibody [EPR10627(B)] (AB154817)

UGPase western blot using anti-UGPase antibody [EPR10627(B)] ab154817. Publication image and figure legend from Sherman, E. J., Mirabelli, C., et al., 2022, PLoS Pathog, PubMed 35231079.

ab154817 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab154817 please see the product overview.

Interrogation of ACE2 modifiers in Calu-3 cells.(A) FACS plots of ACE2 surface staining in Calu-3 cells treated with control nontargeting (NT) or SMAD4-targeting gRNA for each of 3 technical replicates. (B) Volcano plots of MAGeCK Robust Rank Aggregation scores and gene-level gRNA log2 fold-change in ACE2negative relative to ACE2positive populations for each gene tested in the focused CRISPR library in Calu-3 cells. Genes with FDR <0.05 and absolute log2 fold-change >1 are highlighted, with positive regulators in blue and negative regulators in red. (C) Comparison of log2 fold-change in ACE2negative relative to ACE2positive populations in focused CRISPR screens of HuH7 (x-axis) and Calu-3 (y-axis). Only ACE2, highlighted in blue, was identified in both screens with FDR<0.05 and absolute log2 fold-change >1. Genes identified as significant in only the HuH7 or Calu-3 screens are highlighted in magenta and red, respectively. (D) Immunoblot of lysates collected from Calu-3 cells targeted by CRISPR with a gRNA against the indicated gene or a nontargeting (NT) control sequence. (E) Percentage of cells with detectable surface ACE2 staining after CRISPR-mediated single gene disruption of the indicated target gene or a nontargeting control in Calu-3 cells. Candidate genes associated with positive or negative regulation of ACE2 in the CRISPR screen are highlighted in blue and red, respectively. ACE2-positive gates were defined on control unstained cells and the proportion of ACE2-positive cells for each population is displayed for each of 3–6 technical replicates. Error bars depict standard deviation. Asterisks indicate p<0.05 by Student's t-test. Source data and statistical analysis are provided in S9 Table.

false